FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0
|
作者：
Konecny, Gottfried [1 ]
Hendrickson, Andrea Wahner [2 ]
Winterhoff, Boris [3 ]
Chander, Cinthiya [1 ]
Bilic, Sanela [4 ]
Davenport, Simon [5 ]
Chung, Adrine [6 ]
Miller, Lei-Lani [6 ]
Press, Michael [5 ]
Letrent, Stephen [7 ]
Slamon, Dennis [8 ]
机构：
[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA
[2] Mayo Clin, 200 First St Sw, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Vanadro, Pharmacol, Urbandale, IA USA
[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA
[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA
[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR062
引用
收藏
页码：A67 / A67
页数：1
相关论文
共 50 条
  • [11] Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers.
    Ko, Andrew H.
    Coveler, Andrew L.
    Schlechter, Benjamin L.
    Bekaii-Saab, Tanios S.
    Wolpin, Brian M.
    Clark, Jeffrey William
    Bockorny, Bruno
    Bai, Li-Yuan
    Cheng, Yi-Lin
    Cheng, Ting-Ying
    Langecker, Peter J.
    Lin, Shih-Yao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [12] First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Angevin, Eric
    Strickler, John
    Weekes, Colin
    Heist, Rebecca
    Morgensztern, Daniel
    Fan, Xiaolin
    Olyaie, Ozzie
    Motwani, Monica
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S395 - S396
  • [13] First-In-Human Phase 1/2 Trial of Anti-AXL Antibody-Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
    Ramalingam, S.
    Lopez, J.
    Mau-Sorensen, M.
    Thistlethwaite, F.
    Piha-Paul, S.
    Gadgeel, S.
    Drew, Y.
    Janne, P.
    Mansfield, A.
    Chen, G.
    Forssmann, U.
    Johannsdottir, H.
    Pencheva, N.
    Ervin-Haynes, A.
    Vergote, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S209 - S209
  • [14] SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)
    Hollebecque, Antoine
    Lopez, Juanita Suzanne
    Piha-Paul, Sarina A.
    Dowlati, Afshin
    Patnaik, Amita
    Galvao, Vladimir
    Bockorny, Bruno
    Sehgal, Kartik
    Kingsley, Ed
    Sanborn, Rachel E.
    Perez, Cesar Augusto
    Peters, Solange
    Yan, Mingjin
    Nazarenko, Natalya N.
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
    Forero-Torres, A.
    Modi, S.
    Specht, J.
    Miller, K.
    Weise, A.
    Burris, H., III
    Liu, M.
    Krop, I.
    Pusztai, L.
    Kostic, A.
    Li, M.
    Mita, M.
    CANCER RESEARCH, 2017, 77
  • [16] A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
    Boni, Valentina
    Rixe, Oliver
    Rasco, Drew
    Gomez-Roca, Carlos
    Calvo, Emiliano
    Morris, John C.
    Tolcher, Anthony W.
    Assadourian, Sylvie
    Guillemin, Helene
    Delord, Jean-Pierre
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [17] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
    Chandana, Sreenivasa R.
    Choudhury, Noura J.
    Dowlati, Afshin
    Chiang, Anne C.
    Garmezy, Benjamin
    Kim, Joo-Hang
    Byers, Lauren Averett
    Ahn, Myung-Ju
    Kim, Tae Min
    Kim, Young-Chul
    Han, Ji-Youn
    Bar, Jair
    Zha, Jiuhong
    Henner, William
    Robinson, Randy
    Kohlhapp, Fred
    Hingorani, Pooja
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [18] Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji K.
    Migkou, Magdalini
    Bhutani, Manisha
    Spencer, Andrew
    Ailawadhi, Sikander
    Kalff, Anna
    Walcott, Farzana
    Pore, Nabendu
    Gibson, Diana
    Wang, Fujun
    Cheng, Lily
    Kagiampakis, Ioannis
    Williams, Marna
    Kinneer, Krista
    Jiang, Yu
    Zonder, Jeffrey
    Larsen, Jeremy
    Sirdesai, Shreerang
    Yee, Andrew J.
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [19] Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma
    Dimopoulos, Meletios A.
    Migkou, Magdalini
    Bhutani, Manisha
    Ailawadhi, Sikander
    Kalff, Anna
    Walcott, Farzana L.
    Pore, Nabendu
    Brown, Miranda
    Wang, Fujun
    Cheng, Lily I.
    Kagiampakis, Ioannis
    Williams, Marna
    Kinneer, Krista
    Wu, Yuling
    Jiang, Yu
    Kubiak, Robert J.
    Zonder, Jeffrey A.
    Larsen, Jeremy
    Sirdesai, Shreerang
    Yee, Andrew J.
    Kumar, Shaji
    LEUKEMIA & LYMPHOMA, 2024, 65 (12) : 1789 - 1800
  • [20] Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+solid tumors
    Haanen, J. B. A. G.
    Mackensen, A.
    Schultze-Florey, C.
    Alsdorf, W.
    Wagner-Drouet, E.
    Heudobler, D.
    Borchmann, P.
    Busse, A.
    Mielke, S.
    Bins, S.
    Ungerechts, G.
    Bokemeyer, C.
    Klobuch, S.
    Kutsch, N.
    Mueller, F.
    Desuki, A.
    Zhong, W.
    Preussner, L.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2024, 35 : S489 - S490
12345